Browsing: HighTide Therapeutics Inc.

EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies

By Marie JonesSeptember 11, 20240

Highlighting Benefits of Berberine Ursodeoxycholate (HTD1801) HighTide Therapeutics, Inc. (HKG: 2511), a clinical stage biopharmaceutical company specializing in the development…

BioTech

HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801)

By Marie JonesJune 21, 20240

HighTide Therapeutics, Inc. (HKG: 2511), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver…

BioTech

HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801)

By Marie JonesJune 5, 20240

HighTide Therapeutics, Inc. (HKG: 2511), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver…

BioTech

HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study)

By Marie JonesJanuary 11, 20230

HighTide Therapeutics Inc. (HighTide), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today…

BioTech

HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations

By Marie JonesJanuary 5, 20230

Global biopharmaceutical company focusing on metabolic and digestive diseases Proceeds to fund clinical and business development HighTide Therapeutics Inc. (HighTide),…